Clinical Professor of Medicine and Pediatrics, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine
Infectious Disease
Dr. Dean L. Winslow, MD
|
|
Give Review
Dean L. Winslow, MD works in the field of Infectious Disease. He went to Jefferson Medical College. He received 1 awards: "David A. Rytand Excellence in Clinical Teaching Award". Dean Winslow has written publications. He has 38 publications published with PubMed. The lastest publication is: 'Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.' He is registered with Medicare.
Publications
- Treatment as Prevention: Some Additional Thoughts.
- HIV prevention in serodiscordant pair.
- Resistance to HIV integrase inhibitors.
- Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
- Gross hematuria in a young Iraqi man.
- Replication capacity of HIV-1 in the presence of resistance-associated substitutions in protease.
- Guidelines: opportunistic infections and HIV patients.
- Better than nothing: keeping pts on failing regimen has benefits.
- Real world reassurance about a misperception.
- Therapeutic trial of growth hormone releasing factor in HIV patients.
- Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a Latino male.
- Treating the enemy.
- Metabolic syndrome in HIV-infected patients.
- Posaconazole for azole-refractory candidiasis in patients with HIV infection.
- HIV integrase inhibitors show potent activity in clinical trials.
- Hepatocyte apoptosis in hepatitis C/HIV co-infection.
- Wind, rain, flooding, and fear: coordinating military public health in the aftermath of Hurricane Katrina.
- HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.
- Accuracy of the TRUGENE HIV-1 genotyping kit.
- Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.
- Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
- Antibodies reactive with human immunodeficiency virus gag-coded antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a blo...
- Acquired immune deficiency syndrome in Delaware: experience with opportunistic infections and malignancies in 33 patients.
- Aphthous ulceration of the gastrointestinal tract in patients with the acquired immunodeficiency syndrome (AIDS).
- Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.
- Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
- Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per ...
- Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors.
- In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.
- Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene.
- Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors.
- HIV protease inhibitors.
- In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.
- Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
- In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
- Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.
- Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.
Schools
Jefferson Medical College Of Thomas Jefferson University Thomas Jefferson University
Med Center Delaware
Ochsner Fdn
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- David A. Rytand Excellence in Clinical Teaching Award
Education
-
Ochsner Clinic Foundation -
Jefferson Medical College
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1255409835 | |
| NPPES Provider LastName | WINSLOW | |
| NPPES Provider FirstName | DEAN | |
| NPPES Provider ZIPCode | 943042203 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 1745.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255409835 |
| Last Name Of The Provider | WINSLOW |
| First Name Of The Provider | DEAN |
| View All |
Similar Doctors
|
|
Dr. Allan Lavetter, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Harbour, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anitha Gaddipati, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael T. Charney, MD |
|
|
Dr. Robert L. Stiller, MD |
|
|
Dr. Laurence F. Mirels, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rani V. Ramachandran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Gulshan Bhatia, MB |